Roflumilast, a phosphodiesterase-4 inhibitor, induces phagocytic activity in Greek COPD patients

References

• StockleyJAWaltonGMLordJMSapeyEAberrant neutrophil functions in stable chronic obstructive pulmonary disease: the neutrophil as an immunotherapeutic targetInt Immunopharmacol20131741211121723994347
   PubMed Web of Science ®Google Scholar
• FujimotoKUp-to-date COPD treatmentRinsho Byori2014625471477 Japanese25051662
   PubMedGoogle Scholar
• GelsominoFFacchinettiFHaspingerERTargeting the MET gene for the treatment of non-small-cell lung cancerCrit Rev Oncol Hematol201489228429924355409
   PubMed Web of Science ®Google Scholar
• Global Strategy for the Diagnosis, Management, and Prevention of COPDGlobal Initiative for Chronic Obstructive Lung Disease (GOLD) 2015 Available from: http://www.goldcopd.org/guidelines-global-strategy-for-diagnosis-management.htmlAccessed May 19, 2015
   Google Scholar
• AngelisNPorpodisKZarogoulidisPAirway inflammation in chronic obstructive pulmonary diseaseJ Thorac Dis20146Suppl 1S167S17224672691
   PubMed Web of Science ®Google Scholar
• BarnesPJThe cytokine network in chronic obstructive pulmonary diseaseAm J Respir Cell Mol Biol200941663163819717810
   PubMed Web of Science ®Google Scholar
• BarnesPJShapiroSDPauwelsRAChronic obstructive pulmonary disease: molecular and cellular mechanismsEur Respir J200322467268814582923
   PubMed Web of Science ®Google Scholar
• SommerhoffCPNadelJABasbaumCBCaugheyGHNeutrophil elastase and cathepsin G stimulate secretion from cultured bovine airway gland serous cellsJ Clin Invest19908536826892107207
   PubMed Web of Science ®Google Scholar
• AlmagroPSalvadoMGarcia-VidalCRecent improvement in long-term survival after a COPD hospitalisationThorax201065429830220388752
   PubMed Web of Science ®Google Scholar
• KesslerRStahlEVogelmeierCPatient understanding, detection, and experience of COPD exacerbations: an observational, interview-based studyChest2006130113314216840393
   PubMed Web of Science ®Google Scholar
• DecramerMCooperCBTreatment of COPD: the sooner the better?Thorax201065983784120805184
   PubMed Web of Science ®Google Scholar
• DonaldsonGCHurstJRSmithCJHubbardRBWedzichaJAIncreased risk of myocardial infarction and stroke following exacerbation of COPDChest201013751091109720022970
   PubMed Web of Science ®Google Scholar
• WedzichaJASeemungalTACOPD exacerbations: defining their cause and preventionLancet2007370958978679617765528
   PubMed Web of Science ®Google Scholar
• Soler-CatalunaJJMartinez-GarciaMARoman SanchezPSalcedoENavarroMOchandoRSevere acute exacerbations and mortality in patients with chronic obstructive pulmonary diseaseThorax2005601192593116055622
   PubMed Web of Science ®Google Scholar
• PereraWRHurstJRWilkinsonTMInflammatory changes, recovery and recurrence at COPD exacerbationEur Respir J200729352753417107990
   PubMed Web of Science ®Google Scholar
• BhowmikASeemungalTASapsfordRJWedzichaJARelation of sputum inflammatory markers to symptoms and lung function changes in COPD exacerbationsThorax200055211412010639527
   PubMed Web of Science ®Google Scholar
• LahuGNassrNHunnemeyerAPharmacokinetic evaluation of roflumilastExpert Opin Drug Metab Toxicol20117121577159122059647
   PubMed Web of Science ®Google Scholar
• HoggJCChuFUtokaparchSThe nature of small-airway obstruction in chronic obstructive pulmonary diseaseN Engl J Med2004350262645265315215480
   PubMed Web of Science ®Google Scholar
• HatzelmannASchudtCAnti-inflammatory and immunomodulatory potential of the novel PDE4 inhibitor roflumilast in vitroJ Pharmacol Exp Ther2001297126727911259554
   PubMed Web of Science ®Google Scholar
• BundschuhDSEltzeMBarsigJWollinLHatzelmannABeumeRIn vivo efficacy in airway disease models of roflumilast, a novel orally active PDE4 inhibitorJ Pharmacol Exp Ther2001297128029011259555
   PubMed Web of Science ®Google Scholar
• WollinLBundschuhDSWohlsenAMarxDBeumeRInhibition of airway hyperresponsiveness and pulmonary inflammation by roflumilast and other PDE4 inhibitorsPulm Pharmacol Ther200619534335216257550
   PubMed Web of Science ®Google Scholar
• HatzelmannAMorcilloEJLungarellaGThe preclinical pharmacology of roflumilast – a selective, oral phosphodiesterase 4 inhibitor in development for chronic obstructive pulmonary diseasePulm Pharmacol Ther201023423525620381629
   PubMed Web of Science ®Google Scholar
• SanzMJCortijoJMorcilloEJPDE4 inhibitors as new anti-inflammatory drugs: effects on cell trafficking and cell adhesion molecules expressionPharmacol Ther2005106326929715922015
   PubMed Web of Science ®Google Scholar
• Le QuementCGuenonIGillonJYThe selective MMP-12 inhibitor, AS111793 reduces airway inflammation in mice exposed to cigarette smokeBr J Pharmacol200815461206121518493250
   PubMed Web of Science ®Google Scholar
• CalverleyPMRabeKFGoehringUMKristiansenSFabbriLMMartinezFJRoflumilast in symptomatic chronic obstructive pulmonary disease: two randomised clinical trialsLancet2009374969168569419716960
   PubMed Web of Science ®Google Scholar
• FabbriLMCalverleyPMIzquierdo-AlonsoJLRoflumilast in moderate-to-severe chronic obstructive pulmonary disease treated with longacting bronchodilators: two randomised clinical trialsLancet2009374969169570319716961
   PubMed Web of Science ®Google Scholar
• KeatingsVMBarnesPJGranulocyte activation markers in induced sputum: comparison between chronic obstructive pulmonary disease, asthma, and normal subjectsAm J Respir Crit Care Med199715524494539032177
   PubMed Web of Science ®Google Scholar
• CastroAJerezMJGilCMartinezACyclic nucleotide phosphodiesterases and their role in immunomodulatory responses: advances in the development of specific phosphodiesterase inhibitorsMed Res Rev200525222924415514991
   PubMed Web of Science ®Google Scholar
• EssayanDMCyclic nucleotide phosphodiesterase (PDE) inhibitors and immunomodulationBiochem Pharmacol199957996597310796066
   PubMed Web of Science ®Google Scholar
• GrootendorstDCGauwSAVerhooselRMReduction in sputum neutrophil and eosinophil numbers by the PDE4 inhibitor roflumilast in patients with COPDThorax200762121081108717573446
   PubMed Web of Science ®Google Scholar
• ChongJLeungBPoolePPhosphodiesterase 4 inhibitors for chronic obstructive pulmonary diseaseCochrane Database Syst Rev201311CD00230924190161
   PubMed Web of Science ®Google Scholar
• ZhengJYangJZhouXRoflumilast for the treatment of COPD in an Asian population: a randomized, double-blind, parallel-group studyChest20141451445224135893
   PubMed Web of Science ®Google Scholar
• ChoiDRLeeDHChoiCMKimSWSuhCLeeJSErlotinib in first-line therapy for non-small cell lung cancer: a prospective phase II studyAnticancer Res201131103457346221965761
   PubMed Web of Science ®Google Scholar
• HananiaNACalverleyPMDransfieldMTPooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPDRespir Med2014108236637524120253
   PubMed Web of Science ®Google Scholar
• YanJHGuWJPanLEfficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysisPulm Pharmacol Ther2014271838923624309
   PubMed Web of Science ®Google Scholar
• LipariMBenipalHKale-PradhanPRoflumilast in the management of chronic obstructive pulmonary diseaseAm J Health Syst Pharm201370232087209524249758
   PubMed Web of Science ®Google Scholar
• PostmaDAnzuetoACalverleyPA new perspective on optimal care for patients with COPDPrim Care Respir J201120220520921559550
   PubMedGoogle Scholar